President Donald Trump used a speech at the Mack Trucks assembly plant in Macungie, Pennsylvania, to spotlight what his administration calls an unfair burden on American patients.

He argued that European nations, especially Germany, keep drug prices low at the expense of the United States.

The Trump administration launched a formal investigation on June 18 targeting German drug pricing practices. U.S. Trade Representative Jamieson Greer announced the investigation after Germany proposed paying less for medications developed in America.

Officials say the issue goes beyond that single proposal. For years, European nations have negotiated steep discounts with pharmaceutical companies, forcing U.S. firms to sell at lower prices abroad.

Here's What They're Not Telling You About Your Retirement

American patients then face higher costs to offset those losses, according to the administration.

Supporters of the move point out that developing a single new drug can cost about $2.7 billion. When overseas buyers pay less, the administration argues, companies struggle to recover those investments, potentially threatening research and jobs in the United States.

The president has framed the initiative as part of a broader fight against what he describes as economic exploitation by allies.

He likened the standoff to earlier disputes with NATO and European trade policy, saying the U.S. should no longer carry what he sees as Europe’s unfair share of costs.

This Could Be the Most Important Video Gun Owners Watch All Year

Data cited by the administration shows that Americans pay up to four times more than Germans for the same drugs.

“Germans aren’t paying their fair share,” the article argues, accusing Germany of benefiting from American innovation without contributing proportionally to its cost.

Officials in Berlin have criticized the investigation, warning it could jeopardize wider trade talks with the European Union. However, the administration insists it will not compromise on what it considers fair pricing.

The investigation, initiated under Section 301 of U.S. trade law, will examine whether Germany’s policies amount to “persistent underpayment for innovative pharmaceutical products.”

A public hearing is set for September 22, and findings are expected in the fall.

If the administration determines that Germany acted unfairly, it could impose tariffs in retaliation. Trump allies say similar pressure on the United Kingdom led to an agreement for higher payments on U.S. medicines earlier this year.

“This is about fairness and accountability,” the president’s supporters maintain, arguing that other countries should follow the British example. They see the issue not just as economic but also as moral, insisting that nations benefiting from U.S. science must also share its cost.

The administration claims that if Germany increases payments, American patients will benefit through lower prices, and U.S. pharmaceutical companies will have more resources to develop new treatments and cures.

It also sees the move as a message to other nations about paying what the administration considers the true value of U.S. innovation.

Commentator West Cuthbert praised Trump’s approach, saying Germany should reverse course before facing tariffs.

“The U.S. deserves better than a so-called friend who steals our companies’ innovations,” he wrote, urging European leaders to accept that the United States will no longer tolerate what it views as economic imbalance.

For now, the outcome of the investigation remains uncertain. But the episode underscores a defining theme of Trump’s presidency — using trade tools to challenge allies he sees as taking advantage of the United States, this time in the arena of drug pricing.